Product logins

Find logins to all Clarivate products below.


Wet Age-related Macular Degeneration – Epidemiology – Epidemiology – Wet Age-Related Macular Degeneration – Asia Pacific

Clarivate Epidemiology’s coverage of wet age-related macular degeneration (AMD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of wet AMD for each country, as well as annualized case counts projected to the national population.

Patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.

Clarivate Epidemiology’s wet AMD forecast will answer the following questions:

  • Of all people diagnosed with wet AMD, how many in each country in the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of wet AMD over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts 6 wet AMD patient populations, as follows:

  • Total prevalent cases of wet AMD
  • Total prevalent cases of mixed AMD
  • Diagnosed prevalent cases of wet AMD
  • Undiagnosed prevalent cases of wet AMD
  • Diagnosed drug-treated prevalent cases of wet AMD
  • Diagnosed non-drug-treated prevalent cases of wet AMD

Note: Coverage may vary by country.

Related Market Assessment Reports

Report
Chronic Obstructive Pulmonary Disease – Landscape & Forecast – Disease Landscape & Forecast (G7)
The chronic obstructive pulmonary disease (COPD) market continues to gradually shift away from LABA/ICS FDCs toward LABA/LAMA FDCs and LABA/LAMA/ICS FDCs, but current and emerging generics are…
Report
Emerging Vaccines – Landscape & Forecast – Disease Landscape & Forecast (G7)
Vaccination programs have had a revolutionary impact on global public health, not only dramatically reducing the incidence of infectious disease but also reducing childhood and adult mortality and…
Report
Schizophrenia – Landscape & Forecast – Disease Landscape & Forecast (G7)
The schizophrenia therapy market remains very competitive; atypical and typical antipsychotics play a dominant role. While the continued generic erosion of atypical antipsychotics influences…
Report
Squamous Cell Carcinoma of the Head and Neck – Landscape & Forecast – Disease Landscape & Forecast (G7)
Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…
Report
Endometrial Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
The treatment landscape for endometrial carcinoma is rapidly evolving, driven by the growing adoption of immune checkpoint inhibitors and advancements in molecular classification. Although…